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biological siblings living in the same household and in 
those adopted out of the family. This study estimated 
a heritability of 41% for anxiety disorders in families 
aﬀ ected by bipolar disorder. Similarly, psychological 
factors in the origins of anxiety comorbid with bipolar 
disorder have been substantially understudied, although 
recent reports suggest that personality traits such as 
perfectionism might have an important mediating role.9
Finally, research into the development of eﬀ ective 
treatments for patients with this comorbidity has been 
surprisingly scarce. Most clinical therapeutic guidelines, 
whether psychological or pharmacological, extrapolate 
recommended treatments from those developed for 
patients with primary anxiety disorders. Few studies of 
novel treatments for comorbid anxiety in bipolar disorder 
have been reported, with those undertaken suggesting 
some very limited beneﬁ t of psychological treatments 
such as cognitive behavioural therapy,10 or medications 
such as quetiapine, an antipsychotic.11 However, no 
treatments have been shown to be of major eﬀ ect.
In conclusion, Pavlova and colleagues’ meta-
analysis1 conﬁ rms the high prevalence of anxiety dis-
orders comorbid with bipolar disorder. This ﬁ nding, 
in conjunction with growing evidence for increased 
morbidity and mortality for those with this co-occurrence, 
draws attention to the dearth of research into causative 
processes and the development of new treatments. By 
focusing on these issues, Pavlova and colleagues provide a 
much needed and urgent wake-up call for this ﬁ eld.
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 Does cigarette smoking cause psychosis?
Many psychiatrists note that their patients, particularly 
those with schizophrenia, smoke cigarettes—and usually 
smoke heavily. This association has typically been 
assumed to be some form of self-medication, but in 
The Lancet Psychiatry, a systematic review by Pedro Gurillo 
and colleagues1 brings together evidence showing that 
cigarette smoking might actually be a cause of psychosis.
In case-control studies, an overall increase was noted in 
the odds of ﬁ rst-episode psychosis in cigarette smokers 
versus non-smokers (odds ratio 3·22, 95% CI 1·63–6·33), 
albeit with some evidence of publication bias. Daily 
smokers also developed psychotic illness about 1 year 
earlier than did non-smokers. In prospective studies, 
of which only ﬁ ve were identiﬁ ed by the systematic 
review, the relative risk of new psychotic disorders in 
daily smokers versus non-smokers was 2·18 (95% CI 
1·23–3·85). This diﬀ erence in apparent risk by study 
design suggests recall bias in the case-control estimate, 
but the self-medication hypothesis is not mutually 
exclusive with the possibility that smoking is a causal risk 
factor for psychosis. 
The most likely explanation of these ﬁ ndings is that 
cigarette smoking is associated with an increased risk 
for schizophrenia. Taking up, and continuing, smoking 
could be self-medication for anxiety, depression, or 
psychotic symptoms. It could also be shared with other 
risk factors for psychosis, such as family history, urban 
upbringing, or childhood adversity. Each of these risk 
Published Online
July 10, 2015
http://dx.doi.org/10.1016/
S2215-0366(15)00239-4
This online publication 
has been corrected. 
The corrected version ﬁ rst 
appeared at thelancet.com/
psychiatry on July 15, 2015
See Articles page 718
Comment
www.lancet.com/psychiatry   Vol 2   August 2015 673
factors, in addition to early and regular cannabis use, 
seems to have an additive eﬀ ect in terms of phenotypes 
such as psychosis and age at onset.2–4 
Primacy, the strength of an association, dose response, 
and speciﬁ city are among the best indicators of causality 
in an association. Little doubt exists that cigarette 
smoking usually precedes psychosis, but prospective 
studies are scant and few of those published have 
carefully addressed possible confounders. Few readers 
will view a relative risk of 2·18 to be convincing. Smoking 
is also unlikely to be judged a speciﬁ c cause of psychosis. 
Moreover, the age-at-onset data do not really help to 
establish causality, because smoking could advance age 
at onset without necessarily causing psychosis.
One intriguing possible interpretation of these ﬁ ndings is 
that the genes for psychosis overlap with those for cigarette 
smoking. Indeed, they probably do. The Schizophrenia 
Working Group of the Psychiatric Genomics Consortium 
(PGC) described 108 separate genetic loci associated with 
an increased risk of schizophrenia.5 One of these is located 
in a cluster of genes—CHRNA5, CHRNA3, and CHRNB5—
on chromosome 15, and this region is associated with 
both early age at onset of smoking and heavy smoking.6,7 
The PGC might have data available, or could possibly 
gather it, to test the possibility that this genetic proxy for 
heavy smoking is associated with schizophrenia in smokers 
but not in non-smokers and, thus, provide evidence that 
smoking is on the causal pathway to schizophrenia. 
If cigarette smoking is causal, one has to ask why the 
typical age of taking up regular daily smoking is during 
the teenage years, but the usual age at onset of psychosis 
is around 25 years. Regular smoking is unlikely to take 
years to exert a psychotogenic eﬀ ect but, then again, 
most smoking-related diseases only arise after prolonged 
exposure. Perhaps smoking cigarettes acts as a so-called 
gateway drug to cannabis and other psychotomimetics; 
conversely, the association of cannabis with psychosis 
could be attributable to the tobacco with which most 
cannabis is consumed. Thus far, no studies have 
investigated the age at onset of psychotic illness while 
measuring both cannabis and cigarette smoking. In a 
previous meta-analysis, a pooled interval of 5·3 years 
was estimated between age at initiation of daily tobacco 
use and onset of psychosis.8 It is noteworthy in that 
study that the diﬀ erence in age at onset of psychosis in 
cannabis users was 2·7 years, compared with 1·0 years for 
cigarette smokers.1 What is also apparent from published 
work is that co-use of both cigarettes and cannabis 
is common in young people and is associated with a 
worsening of mental health symptoms.9 Kandel and 
Kandel10 have summarised an impressive amount of 
in vitro and in vivo work, in keeping with the view that 
tobacco is a gateway drug to other substances of misuse, 
but epidemiological evidence is, as yet, absent.
Large, longitudinal, prospective studies are needed 
to investigate the relations between smoking tobacco 
and cannabis and development of anxiety, depression, 
and psychotic disorders, adjusting for the eﬀ ects of 
other substances, to enable more stringent examination 
of whether cigarette smoking has a causal role in the 
development of psychosis. Such studies will allow us 
to assess the public health importance of the results 
presented here. To say that smoking causes psychosis 
would be premature, but the time might not be too 
much longer before cigarette smoking is recognised as a 
risk factor for psychosis as well as anxiety and depression. 
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